Plus Therapeutics, Inc. provided revenue guidance for the fourth quarter of 2023 and calendar year of 2024. The company forecasts grant revenue of between $1 million to $1.5 million in fourth quarter of 2023 and between $6 million to $7 million for calendar year 2024.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.09 USD | -4.13% | -5.07% | +17.71% |
May. 15 | Transcript : Plus Therapeutics, Inc., Q1 2024 Earnings Call, May 15, 2024 | |
May. 09 | Transcript : Plus Therapeutics, Inc. - Special Call |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+17.71% | 9.32M | |
+43.38% | 54.04B | |
+43.57% | 41.96B | |
-1.27% | 41.92B | |
-7.59% | 28.35B | |
+11.90% | 26.35B | |
-21.90% | 19B | |
+7.65% | 13B | |
+29.16% | 12.28B | |
+25.49% | 12.19B |
- Stock Market
- Equities
- PSTV Stock
- News Plus Therapeutics, Inc.
- Plus Therapeutics, Inc. Provides Revenue Guidance for the Fourth Quarter of 2023 and Calendar Year of 2024